| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 30.73▲ | 30.98▼ | 30.95▼ | 34.30▼ | 36.94▼ |
| MA10 | 30.85▼ | 30.93▼ | 31.26▼ | 36.38▼ | 38.21▼ |
| MA20 | 30.88▼ | 31.57▼ | 33.37▼ | 37.84▼ | 35.80▼ |
| MA50 | 30.90▼ | 34.57▼ | 36.47▼ | 38.71▼ | 31.09▼ |
| MA100 | 31.10▼ | 36.67▼ | 37.62▼ | 35.98▼ | 26.88▲ |
| MA200 | 33.04▼ | 37.75▼ | 39.14▼ | 32.22▼ | 31.60▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.029▼ | 0.168▲ | -0.110▼ | -0.906▼ | -0.718▼ |
| RSI | 44.949▼ | 32.119▼ | 28.932▼ | 22.937▼ | 42.452▼ |
| STOCH | 9.236▼ | 53.776 | 11.064▼ | 25.354 | 39.886 |
| WILL %R | -87.402▼ | -72.766 | -93.443▼ | -96.794▼ | -97.559▼ |
| CCI | -74.295 | -74.826 | -60.989 | -196.271▼ | -125.174▼ |
|
Wednesday, September 23, 2026 04:00 AM
When biopharmaceutical companies advance platform technologies targeting complex immunological pathways, market participants must weigh clinical efficacy against the heavy capital requirements of drug ...
|
|
Tuesday, September 22, 2026 09:02 AM
Celldex Therapeutics (NASDAQ:CLDX) reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained ...
|
|
Tuesday, September 22, 2026 07:29 AM
US biopharma Celldex Therapeutics said its Phase III EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab both met their primary endpoint and all key secondary endpoints in patients with chronic ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 24/09/26 | 31.00 | 31.305 | 30.635 | 30.75 | 408,877 |
| 23/09/26 | 33.54 | 33.59 | 30.405 | 31.12 | 4,235,974 |
| 22/09/26 | 36.60 | 38.39 | 30.39 | 33.51 | 12,869,195 |
| 21/09/26 | 41.62 | 41.62 | 37.48 | 37.89 | 548,274 |
| 18/09/26 | 38.87 | 38.87 | 37.535 | 38.24 | 2,079,178 |
| 17/09/26 | 39.47 | 40.66 | 38.92 | 38.98 | 1,276,852 |
| 16/09/26 | 38.59 | 39.21 | 38.25 | 38.71 | 999,536 |
| 15/09/26 | 39.00 | 39.19 | 37.74 | 38.51 | 685,458 |
| 14/09/26 | 37.40 | 39.42 | 37.27 | 39.18 | 998,683 |
| 11/09/26 | 38.39 | 38.59 | 36.84 | 36.90 | 1,032,789 |
|
|
||||
|
|
||||
|
|